These observations imply that the therapeutic approaches targeting chromosome17q21-22 region encoding topoisomerase IIα and HER2 proteins may benefit patients with high-grade salivary gland carcinomas. The gene discussed is ERBB2; the disease is salivary gland carcinoma.